Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546
info@example.com

Related Posts

Products

Weil-Felix

The Weil-Felix test was developed by Weil and Felix in 1916. It is a heterophile agglutination test due to the antigenic sharing between species of proteus and rickettsia. Antibodies produced against rickettsial antigen cross reacts with OX19 and OX2 strains of Proteus vulgaris and OXK strains of Proteus mirabilis. Proteus stained febrile antigen suspensions can be used to identify and quantitate specific antibodies in human sera following infection with certain Rickettsiae pathogens. Proteus OX19 reacts strongly with the sera of patients with typhus group rickettsae and rocky mountain of spotted fever, Proteus OX2 reacts strongly with sera of patients with spotted fever infections, while the Proteus OXK reacts strongly with the sera of patients infected with scrub typhus.

The Biorex Diagnostics Febrile Antigens Weli-Felix test is prepared for the rapid detection and semi-quantitation of serum antibodies developed during the acute stage of disease. The antigens agglutinate in the presence of the homologous antibodies in the sample tested.

Add to Quote

Description

Product Name CAT.No Size
Weil-Felix FEWF0025 5 x 5ml

 

 

Product Description

The Biorex Diagnostics Weil-Felix Test is a rapid slide agglutination assay designed for the qualitative and semi-quantitative detection of antibodies produced in response to Rickettsial infections. Utilizing Proteus OX19, OX2, and OXK stained febrile antigen suspensions, this test provides a reliable and practical method for the early identification of typhus, spotted fever, and scrub typhus. Its simple and rapid procedure makes it ideal for clinical laboratories, hospitals, diagnostic centres, and public health settings where timely detection and patient management are critical.

Key Features

  • High sensitivity and specificity – detects antibodies against multiple clinically significant Rickettsial pathogens.
  • Rapid visual results – clear agglutination visible within minutes, allowing fast interpretation.
  • Semi-quantitative capability – enables titre estimation to monitor disease progression, response to therapy, and convalescence.
  • Versatile sample use – compatible with human serum and plasma for routine, diagnostic, and follow-up testing.
  • Cost-effective and ready-to-use – suitable for large-scale screening, epidemiological studies, and public health surveillance programmes.

Benefits
Routine use of the Weil-Felix Test allows healthcare providers to detect abnormal antibody responses efficiently, supporting early diagnosis, timely intervention, and effective patient management. Its ready-to-use format eliminates preparation errors, simplifies workflow, and ensures consistent, reproducible results. The semi-quantitative capability provides clinicians with valuable information on antibody titres, assisting in the monitoring of infection progression or recovery.

Beyond individual patient care, the Weil-Felix Test is an essential tool for public health authorities and epidemiologists. It enables rapid outbreak monitoring, early identification of Rickettsial epidemics, and guidance for disease prevention and control initiatives. By integrating this assay into standard laboratory protocols, clinical teams can enhance diagnostic accuracy, support efficient laboratory operations, and improve patient outcomes. Its combination of speed, reliability, and clinical relevance makes it indispensable for hospital laboratories, diagnostic centres, and research facilities focused on infectious disease surveillance and Rickettsial infection management.

Contact Us for more information.

Additional information

Storage

2-8°C